![]() During the year we added capacity for bioproduction, sterile fill-finish services, laboratory products as well as enzymes and nucleotides. Accelerated investments in capacity and capabilities, investing $2.5 billion in 2021 to meet short- and long-term customer demand.During the quarter, we launched the Thermo Scientific Orbitrap Exploris MX mass detector providing high throughput analysis to improve the development and production of biopharmaceuticals and the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR system which enables clinical testing laboratories to accelerate molecular diagnostics. Delivered another year of high-impact innovation, highlighted by the HyPerforma DynaDrive Single-Use Bioreactor, the Thermo Scientific Orbitrap Exploris Gas Chromatography-Mass Spectrometers, and the Thermo Scientific Helios 5EXL Wafer DualBeam scanning electron microscope to support the development of increasingly smaller and more complex semiconductors.Achieved very strong results in the fourth quarter, with excellent growth in the base business and $2.45 billion of COVID-19 response revenue.Built on industry leadership throughout the year, supporting our customers, delivering outstanding results, and investing to further strengthen the long-term growth trajectory of the company. ![]() Full year adjusted EPS increased 28% to $25.13.Full year GAAP diluted EPS increased 22% to $19.46.Full year revenue grew 22% to $39.21 billion.Fourth quarter GAAP diluted earnings per share (EPS) was $4.17.Fourth quarter revenue was $10.70 billion.(NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021.įourth Quarter and Full Year 2021 Highlights 2, 2022 /PRNewswire/ - Thermo Fisher Scientific Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |